CD8A and melanoma: Previous studies showed that intratumoral administration of rabbit erythrocyte-derived α-Gal glycolipids into B16 melanoma lesions led to CD8+ T cell-mediated immunity to MAAs as well as to OVA as a surrogate TSA, proving the mechanism of α-Gal glycolipid-induced anti-tumor immunity [15, 16].